Trial Profile
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Brain metastases; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Registrational
- Sponsors Boehringer Ingelheim Pharmaceuticals; Unilfarma
- 25 Mar 2024 Status changed from active, no longer recruiting to completed.
- 12 Dec 2023 Planned End Date changed from 31 Dec 2023 to 1 Apr 2024.
- 23 Jan 2023 Planned End Date changed from 31 Mar 2023 to 31 Dec 2023.